[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100350967":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":34,"locations":35,"responsibleParty":49,"collaborators":34,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":34,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":34,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":72,"whyStopped":34,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TAK-906 25 mg; Esomeprazole 40 mg + TAK-906 25 mg","EXPERIMENTAL","TAK-906 25 milligram (mg), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 4 days, further followed by esomeprazole 40 mg, capsule, orally, once daily on Days 1 to 5 along with TAK-906 25 mg, capsule, orally, once on Day 4 of Study Period 2.",[13,14],"Drug: TAK-906","Drug: Esomeprazole",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","TAK-906","TAK-906 capsules.",[9],[22],"TAK-906 maleate",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Esomeprazole","Esomeprazole capsules.",[9],[28],"Nexium",[30],{"name":31,"affiliation":32,"role":33},"Medical Director","Millennium Pharmaceuticals, Inc.","STUDY_DIRECTOR",null,[36],{"facility":37,"status":34,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":34},"Celerion","Tempe","Arizona","85283","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-111.90931,33.41477,{"lat":47,"lon":46},{"type":50,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100350967","phase-1-a-trial-to-evaluate-the-effect-of-the-proton-pump-inhibitor-esomeprazole-on-the-single-dose-pharmacokinetics-pk-of-oral-tak-906-in-healthy-adult-participants-100350967",true,"NCT03849690","A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants","A Single-Sequence, Open-Label, 2-Period, Crossover Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics of Oral TAK-906 in Healthy Adult Subjects","Inclusion Criteria:\n\n1. Continuous non-smoker who has not used nicotine containing products for at least 3 months prior to the first dosing and throughout the study, based on screening urine cotinine test.\n2. Has a body mass index (BMI) greater than or equal to (\\>=) 18 and less than or equal to (\\\u003C=) 30 kilogram per square meter (kg\u002Fm\\^2) at Screening.\n\nExclusion Criteria:\n\n1. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.\n2. QT interval corrected using Fridericia's formula (QTcF) interval is greater than (\\>) 450 millisecond (msec) or ECG findings are deemed abnormal with clinical significance by the Investigator or designee at screening.\n3. Donation of blood or significant blood loss (example, approximately 500 milliliter \\[mL\\]) within 56 days prior to the first dosing.\n4. Plasma donation within 7 days prior to the first dosing.\n5. Participation in another clinical study within 30 days or 5 half-lives prior to the first dosing. The 30 day window or 5 half-lives will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Study Period 1 of the current study.","ALL","18 Years","55 Years",{"count":62,"type":63},12,"ACTUAL","INTERVENTIONAL",[66],"PHASE1","The purpose of this study is to evaluate the effect of the proton pump inhibitor (PPI) esomeprazole on the single-dose PK of orally administered TAK-906.",[69],"Healthy Volunteers",[71],"Drug Therapy","COMPLETED","2021-05-27",{"date":75,"type":63},"2021-06-15",{"date":77,"type":63},"2019-02-27",{"date":79,"type":63},"2019-04-15",{"name":32,"class":6},1]